Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia

• Status: Completed
• Trial end date: 2018-01-10
• Target enrollment: 0
• Participant gender: All

Summary

To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin alone in the treatment of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Miquel Pujol
• Collaborator: Hospital Universitari de Bellvitge
• Treatments: Daptomycin; Fosfomycin

Criteria

Inclusion Criteria:

• Patients with at least 1 positive blood culture to MRSA within 72h up to randomization

• Adult patients, equal or older than 18 years old

• Signed informed consent

• Mandatory use of contraception methods for fertile women during the study period and for 6 months after stopping antibiotic therapy

Exclusion Criteria:

• Polymicrobial bacteremia

• Pneumonia associated to the bacteremia

• Severe clinical status with expected survival of less than 24 hours

• Allergy to daptomycin or fosfomycin

• A positive pregnancy test at the time of inclusion

• Any clinical condition that requires additional antibiotic therapy with microbiological activity against MRSA

• Patient already included in another clinical trial

• Prior history of eosinophilic pneumonia